Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

5.17USD
20 Apr 2018
Change (% chg)

$-0.48 (-8.50%)
Prev Close
$5.65
Open
$5.59
Day's High
$5.64
Day's Low
$5.16
Volume
5,327
Avg. Vol
13,028
52-wk High
$15.19
52-wk Low
$4.84

Select another date:

Fri, Apr 20 2018

BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates

* ARCTURUS THERAPEUTICS FILES LAWSUIT AGAINST JOSEPH E. PAYNE AND HIS ASSOCIATES FOR VIOLATIONS OF FEDERAL SECURITIES LAWS

BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM

* JOSEPH E. PAYNE -ON APRIL 18, SENT LETTER TO ARCTURUS THERAPEUTICS LTD. BOARD TO RESTATE HIS PRIOR DEMAND TO CONVENE EGM OF SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2F05p2z) Further company coverage:

BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"

* JOSEPH PAYNE SAYS CALLING ON ARCTURUS THERAPEUTICS' BOARD TO HOLD ITS EXTRAORDINARY GENERAL MEETING "WITHOUT FURTHER DELAY"

BRIEF-‍Arcturus Therapeutics Initiates Lawsuit Against Former CEO Joseph Payne

* ‍ARCTURUS THERAPEUTICS INITIATES LAWSUIT AGAINST FORMER PRESIDENT AND CEO JOSEPH PAYNE

BRIEF-Arcturus Therapeutics issues statement on extraordinary general meeting of shareholders

* ARCTURUS THERAPEUTICS - ‍CO SOUGHT TO APPOINT NEW INDEPENDENT AUDITOR IN ORDER TO REPORT FINANCIAL RESULTS, INCLUDING ITS FINANCIAL STATEMENTS FOR 2017​

BRIEF-Arcturus Therapeutics Comments On Amended 13D Filing

* ARCTURUS THERAPEUTICS LTD - COMMENTED ON AMENDED 13D FILING BY JOSEPH E. PAYNE

BRIEF-Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics

* JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE

BRIEF-Certain Arcturus Therapeutics Shareholders Expressed Support For Former CEO Joseph Payne's Leadership

* FORMER CEO JOSEPH PAYNE SAYS HE WAS APPROACHED BY CERTAIN ARCTURUS THERAPEUTICS SHAREHOLDERS, WHO EXPRESSED SUPPORT FOR HIS CONTINUED LEADERSHIP

BRIEF-Arcturus Therapeutics Appoints Mark Herbert As Interim President

* ARCTURUS THERAPEUTICS APPOINTS MARK HERBERT AS INTERIM PRESIDENT

BRIEF-Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017

* BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING

Select another date: